QI
LRMR icon

QS Investors’s Larimar Therapeutics LRMR Stock Holding History

QS Investors’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-92
Closed -$13K – 1915
2018
Q3 		$13K Hold
92
– – ﹤0.01% 1524
2018
Q2 		$11K Hold
92
– – ﹤0.01% 1559
2018
Q1 		$8K Hold
92
– – ﹤0.01% 1572
2017
Q4 		$5K Hold
92
– – ﹤0.01% 1607
2017
Q3 		$4K Hold
92
– – ﹤0.01% 1637
2017
Q2 		$4K Hold
92
– – ﹤0.01% 1642
2017
Q1 		$5K Buy
+92
New +$4.57K ﹤0.01% 1674

Other funds holding LRMR

GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
AVA
Atlas Venture Advisors Boston, Massachusetts $143M AUM 25.68% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

QS Investors's LRMR Position: Q4 2018 in Review

QS Investors sold out of Larimar Therapeutics (LRMR) in Q4 2018, closing a stake of 92 shares — an estimated $13K sold.

QS Investors first reported a position in LRMR in Q1 2017 and held it in 7 quarters. The position peaked at $13K in Q3 2018. 94 funds tracked by Wall St. Rank hold LRMR as of Q4 2018.

  • QS Investors reported no remaining Larimar Therapeutics position as of Q4 2018 after selling out during the quarter.
  • QS Investors sold 92 Larimar Therapeutics shares in Q4 2018, an estimated $13K.
  • QS Investors first reported a position in Larimar Therapeutics in Q1 2017 and held it in 7 quarters.
  • QS Investors's Larimar Therapeutics position peaked at $13K in Q3 2018.
  • 94 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q4 2018.

Based on QS Investors's 13F filing for Q4 2018, filed 14 Feb 2019.